---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-023263"
form_type: "8-K"
ticker: "BTCY"
cik: "0001630113"
company_name: "BIOTRICITY INC."
filed_at: "2022-08-17T23:59:59+00:00"
generated_at: "2026-06-23T23:08:59.915973+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Biotricity reports Q1 FY2023 revenue $2.1M, net loss $5M, launches Biotres and Bioheart

## Summary
- Revenue $2.1M; gross margin 60% consistent with FY22; net loss $5M ($0.098/sh); adjusted loss $0.085/sh.
- Launched Biotres wireless holter patch after FDA clearance; also launched Biokit and Bioheart.
- Expanded physician network to 29 states with over 2,000 physicians using products.

## SEC filing metadata
- accession: 0001493152-22-023263
- form_type: 8-K
- ticker: BTCY
- cik: 0001630113
- company_name: BIOTRICITY INC.
- filed_at: 2022-08-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630113/000149315222023263/0001493152-22-023263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630113/000149315222023263/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-023263
- JSON: https://secwatch.observer/filing/0001493152-22-023263.json
- Plain text: https://secwatch.observer/filing/0001493152-22-023263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.